Ads
-
Related paper
- PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION
- The relationship between the dose of continuous erythropoietin receptor activator and oxidative stress in hemodialysis patients
- Erythropoietin (Epo), Erythropoietin Receptor (EpoR) and Red Cell Development- Deciphering Molecular Connections
- Expression of Erythropoietin and Erythropoietin Receptor in Oral Squamous Cell Carcinoma
- EFFICACY AND SAFETY OF IRON (III)–HYDROXIDE SUCROSE COMPLEX IN CORRECTION OF ANEMIA STAGE 5D CHRONIC KIDNEYDISEASE HEMODIALYSIS PATIENTS NOT TREATED BY ERYTHROPOIESIS–STIMULATING AGENTS (PROSPECTIVEANALYSIS)
- Caffeic Acid Inhibited Receptor Activator of Nuclear Factor kappaB Ligand (RANKL)-Tumor Necrosis Factor (TNF) alpha-TNF Receptor Associated Factor (TRAF) 6 Induced Osteoclastogenesis Pathway
- Serum transferrin receptor levels in iron deficiency anemia and anemia of chronic disease
- Does erythropoietin therapy affect circulating endothelial cells in hemodialysis patients?
- AN OBSERVATIONAL STUDY ON- MANAGEMENT OF ANEMIA IN CKD USING ERYTHROPOIETIN ALPHA
- Predicting Resistance to Recombinant Human Erythropoietin Therapy in CKD Patients on Maintenance Hemodialysis